
Linda Martin, MD, joined the University of Virginia, School of Medicine faculty and the UVA Cancer Center as an associate professor of surgery in 2016. Dr. Martin received her medical degree from the University of California, San Diego. Her surgical internship and residency training began at the University of Minnesota, and midway through she transferred to complete her training at the University of California, San Francisco. She then specialized in general thoracic surgery, with thoracic track fellowship training at MD Anderson Cancer Center in Houston, TX. Dr. Martin also obtained a post-doctorate master’s degree in public health from the University of Texas, Houston.
As chief of thoracic surgery, Dr. Martin focuses on thoracic malignancies, but she also has extensive experience with benign lung and esophageal diseases. She is a strong advocate for lung cancer screenings and collaborates with physicians and healthcare providers from all disciplines to determine the best treatment strategy. She also helps encourage patients to quit smoking.
Dr. Martin has an interest in robotic surgery, which she was trained to perform through the Carolyn E. Reed Traveling Fellowship. Clinical trials research is another strong interest of hers. She strives to offer trials to any patients who may qualify, and she is heavily involved in design and implementation of clinical research through her work and leadership within several committees of the Alliance for Clinical Trials in Oncology, an NCI sponsored group. She also has collaborated with anesthesiologists and nursing staff to develop enhanced recovery after thoracic surgery pathways to improve outcomes and shorten hospital stay for patients undergoing chest surgery.
Selected publications from PubMed
Things to Consider While Negotiating Your Contract: A Report From The Society of Thoracic Surgeons Workforce on Cardiothoracic Surgery Practice.
Spurlock D, Squiers JJ, Martin LW, Kaiser LR, DiMaio JM, Society of Thoracic Surgeons Workforce on Cardiothoracic Surgery Practice
Ann Thorac Surg. 2026 Sep;122(3):773-781 doi: 10.1016/j.athoracsur.2026.03.078.
CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes.
Martin LW, Wang X, Kozono D, Urbanic J, Bharat A, Crye M, Ferguson MK, Kim SS, Wallen J, Patel JD, Stinchcombe TE
Ann Thorac Surg. 2026 Aug 5 pii: S0003-4975(26)00815-5. doi: 10.1016/j.athoracsur.2026.07.041.
The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.
Linden PA, Martin LW, Stiles B, Opitz I, Chen H, Spicer J, Lanuti M, Tong BC, Liberman M, Bestvina CM, Sands J, Huang J, Price M, Samson P, Boutros CS, Rabinovich EP, Park B, D'Amico TA
J Thorac Cardiovasc Surg. 2026 Aug;172(2):450-466.e2 doi: 10.1016/j.jtcvs.2026.03.622.
Eligibility for Lung Cancer Screening Under the 2021 US Preventive Services Task Force Recommendation Between Patients Diagnosed With Early vs Late-Stage Lung Cancer: Analysis of 3 Cohort Studies.
Potter AL, Guo Q, Rettner B, Zhu A, Potter AL, Zheng W, Kothari J, Shafer A, Martin LW, Pasquinelli MM, Christiani DC, Jeffrey Yang CF
Chest. 2026 Aug;170(2):593-603 doi: 10.1016/j.chest.2026.01.033.
Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery.
Rabinovich EP, Martin LW
J Clin Med. 2026 Jun 10;15(12) doi: 10.3390/jcm15124493.
Help your network discover Dr. Linda Martin's clinical expertise.